Beam Historical Cash Flow
| BEAM Stock | USD 28.68 2.11 6.85% |
Analysis of Beam Therapeutics cash flow over time is an excellent tool to project Beam Therapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 119.1 M or Other Cashflows From Financing Activities of 7.3 M as it is a great indicator of Beam Therapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Beam Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Beam Therapeutics is a good buy for the upcoming year.
Beam |
About Beam Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Beam balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Beam's non-liquid assets can be easily converted into cash.
Beam Therapeutics Cash Flow Chart
Add Fundamental
Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Capital Expenditures
Capital Expenditures are funds used by Beam Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Beam Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Beam Therapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Beam Therapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.At this time, Beam Therapeutics' Change In Cash is very stable compared to the past year. As of the 26th of February 2025, Stock Based Compensation is likely to grow to about 119.1 M, though Change In Working Capital is likely to grow to (127.2 M).
| 2022 | 2024 | 2025 (projected) | Change To Netincome | 16.9M | 19.5M | 18.5M | Issuance Of Capital Stock | 108.3M | 308.7M | 306.4M |
Beam Therapeutics cash flow statement Correlations
Click cells to compare fundamentals
Beam Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Beam Therapeutics cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 126.5M | 395.7M | (327.2M) | 199.1M | 229.0M | 240.4M | |
| Stock Based Compensation | 15.4M | 43.6M | 84.3M | 98.6M | 113.4M | 119.1M | |
| Free Cash Flow | (112.1M) | (113.1M) | (26.4M) | (182.9M) | (164.6M) | (156.4M) | |
| Change In Working Capital | 5.3M | 111.3M | 251.6M | (116.5M) | (133.9M) | (127.2M) | |
| Other Cashflows From Financing Activities | 1.1M | 810K | 5.6M | 8.5M | 7.7M | 7.3M | |
| Depreciation | 4.7M | 7.5M | 14.1M | 20.0M | 23.0M | 24.2M | |
| Other Non Cash Items | 9.9M | 158.9M | (38.5M) | (18.9M) | (17.0M) | (16.1M) | |
| Capital Expenditures | 16.4M | 46.8M | 49.0M | 33.7M | 38.8M | 27.0M | |
| Total Cash From Operating Activities | (95.7M) | (66.3M) | 22.5M | (149.2M) | (134.3M) | (127.6M) | |
| Net Income | (194.6M) | (370.6M) | (289.1M) | (132.5M) | (119.3M) | (125.2M) | |
| Total Cash From Financing Activities | 322.3M | 756.1M | 111.6M | 276.4M | 317.9M | 266.0M | |
| End Period Cash Flow | 177.0M | 572.7M | 245.5M | 444.6M | 511.3M | 257.8M | |
| Investments | (83.0M) | (248.0M) | (461.3M) | 87.2M | 78.5M | 82.4M | |
| Begin Period Cash Flow | 50.6M | 177.0M | 572.7M | 245.5M | 282.3M | 219.2M | |
| Total Cashflows From Investing Activities | (66.7M) | (100.1M) | (294.1M) | (461.3M) | (415.2M) | (394.4M) | |
| Change To Operating Activities | (14.8M) | 5.3M | (237.7M) | (14.8M) | (13.3M) | (14.0M) | |
| Issuance Of Capital Stock | 319.5M | 757.4M | 108.3M | 268.5M | 308.7M | 306.4M | |
| Change To Netincome | 13.5M | 88.8M | 185.7M | 16.9M | 19.5M | 18.5M | |
| Change To Liabilities | 4.1M | 60K | 349.0M | (33.5M) | (38.6M) | (36.7M) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Beam Therapeutics. If investors know Beam will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Beam Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.58) | Revenue Per Share | Quarterly Revenue Growth (0.17) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Beam Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Beam Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Beam Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.